Checkpoint blockade in esophagogastric cancer. Issue 1 (7th June 2018)

• Record Type: Journal Article
• Authors: Cohen, Noah A.; Strong, Vivian E.; Janjigian, Yelena Y.
• Is Part Of: Journal of surgical oncology. Volume 118:Issue 1(2018)
• Page Start: 77
• Page End: 85
• Publication Date: 2018-06-07
• Subjects: checkpoint inhibitor -- gastric -- gastroesophageal -- immunotherapy -- PD‐1; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.25116
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract : There are few effective treatment options for metastatic esophagogastric adenocarcinomas after progression on second‐line chemotherapy. Immune checkpoint blockade therapy is a promising treatment strategy for selected advanced esophagogastric cancer, and the PD‐1 inhibitor pembrolizumab has recently been approved for metastatic or recurrent gastric or gastroesophageal junction cancer that has progressed beyond second‐line systemic therapy. We review the current data supporting immune checkpoint blockade therapy in advanced esophagogastric adenocarcinoma.